Orthofix Q3 net sales $196.6M (+7%), adjusted EBITDA $19.2M, introduces 2027 targets

Orthofix Medical Inc.

2024-Q3 EPS reported -$2.55 revenue$583,834,000

Net sales $196.6M, +7% YoY; U.S. Spine Fixation +18%, U.S. Orthopedics record quarter +15%.
Net loss $(27.4)M vs $(28.9)M prior year; adjusted EBITDA $19.2M, margin 9.8% vs 7.3%.
Free cash flow positive $5.9M in Q3; new $275M credit facility announced.
Reiterates FY2024 guidance: net sales $795-800M, adjusted EBITDA $64-69M.
Introduces 2027 targets: 6-7% revenue CAGR, mid-teens adjusted EBITDA margin, positive FCF.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.